Blinatumomab is an injectable drug that acts as an antibody, joins the membranes of cancer cells and allows the immune system to identify them more easily; as a result, defense cells are easier to remove cancer cells, especially in cases of acute lymphoblastic disease.Leukemia.
This medicine can also be known commercially as Blincyto and should only be used in the hospital for the treatment of cancer, under the direction of an oncologist.
- This medicine cannot be purchased from conventional pharmacies.
- It is only used during cancer treatment in hospitals or specialized centers.
- Such as INCA for example.
Blinatumomab is indicated for the treatment of acute B-cell precursor leukemia, negative Philadelphia chromosome, relapsing or refractory.
The dose of blinatumomab to be administered should always be guided by an oncologist, as it varies depending on the characteristics of the person and the stage of the disease.
Treatment is performed with 2 cycles of 4 weeks each, separated by 2 weeks, and should be hospitalized during the first 9 days of the first cycle and for 2 days of the second cycle.
The most common side effects of using this remedy include anemia, excessive fatigue, low blood pressure, insomnia, headache, tremors, dizziness, cough, nausea, vomiting, constipation, abdominal pain, back pain, fever, joint pain, chills and changes in blood tests.
Blinatumomab is indicated for breastfeeding women and people allergic to any of the ingredients of the formula, in addition, in the case of pregnant women, it should only be used with the advice of the obstetrician.